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### Cognition After Lowering LDL Cholesterol With Evolocumab ![](fx1_lrg.gif) {#sec1.1.1}
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The authors observed that patients treated with evolocumab as well as those who achieved progressively very low low-density lipoprotein cholesterol (LDL-C) at 4 weeks in the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) trial had similar patient-reported cognition in comparison with placebo and those with higher achieved LDL-C levels, extending previous findings reported in the EBBINGHAUS (Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk Subjects) trial. These data confirm the neurocognitive safety of intensive LDL-C reduction with evolocumab, while reducing recurrent cardiovascular events in high-risk patients, and suggest that very low achieved LDL-C levels may be safely targeted for high-risk patients.
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### Low LDL-C Levels: Likely No Short-Term Cognitive Harm {#sec1.2.1}
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### Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial ![](fx1_lrg.gif) {#sec1.3.1}
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Extrapolating health outcomes of patients in ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) resulted in an incremental cost-effectiveness ratio below US\$100,000 per quality-adjusted life-year for alirocumab at a cost of US\$5,850 per year. The incremental cost-effectiveness ratio was less than US\$50,000 per quality-adjusted life-year among patients with baseline low-density lipoprotein cholesterol (LDL-C) ≥100 mg/dl. At a list price of US\$5,850, alirocumab represents good value in acute coronary syndromes patients with baseline LDL-C ≥100 mg/dl despite statin therapy, though less value in patients with LDL-C \<100 mg/dl.
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### PCSK9 Inhibition for Therapeutic Decision-Making: Assessing the Value {#sec1.4.1}
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### Atrial Septal Aneurysm, Shunt Size, and Recurrent Stroke Risk in Patients With Patent Foramen Ovale ![](fx1_lrg.gif)![](fx3_lrg.gif) {#sec1.5.1}
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The authors pooled individual patient data from 4 prospective studies with the aim of disentangling the respective influence of shunt size and atrial septal aneurysm status on stroke recurrence in patients with recent patent foramen ovale (PFO)--related stroke treated medically. Atrial septal aneurysm was significantly associated with the risk of stroke recurrence, whereas large PFO was not, with a heterogeneity across studies. These results could help to better identify those patients with a high risk of stroke recurrence under medical therapy who might derive the most benefit from PFO closure due to a higher absolute risk reduction.
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### Risk Management: "High-Risk" PFOs Come Into Partial Focus {#sec1.6.1}
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### Incidence and Long-Term Outcomes of Hypertensive Disorders of Pregnancy ![](fx1_lrg.gif) {#sec1.7.1}
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Using a population-based study, we reported that the incidence of hypertensive disorders of pregnancy expressed per-pregnancy (7.3%) underestimated the number of affected women after their reproductive years (15.3%). Women with a history of hypertensive disorders of pregnancy, compared with those with normotensive pregnancies, demonstrated significant increased risks for both kidney and cardiovascular disease, even at a relatively young median age of 60 years, and multimorbidity, a measure of accelerated aging.
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### Women's Cardiovascular Health After Hypertensive Pregnancy: The Long View From Labor and Delivery Becomes Clearer {#sec1.8.1}
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### Long-Term Outcomes of Primary Cardiac Malignancies: Multi-Institutional Results From the National Cancer Database ![](fx1_lrg.gif) {#sec1.9.1}
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Of 100,317 patients who were diagnosed with cardiac malignancies, 826 (0.8%) were found to be primary in origin. The majority (89.9%) of these were sarcomas. The overall 5-year survival was poor at 11.5%. Patients who were selected for surgery had a survival benefit at 5 years. Peri-operative chemotherapy in stage III patients was also associated with better survival. Increase in age, Charlson comorbidity index, hemangiosarcoma, and presence of metastases were associated with poor survival at 5 years.
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### Primary Cardiac Malignancies: The Need for a Multidisciplinary Approach and the Role of the Cardio-Oncologist {#sec1.10.1}
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### Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic ![](fx1_lrg.gif) {#sec2.1.1}
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Coronavirus disease 2019 (COVID-19) has placed an unprecedented burden on health care systems throughout the world. This review presents a comprehensive description of the interplay between cardiovascular disease and COVID-19, including the risk for severe disease among those with pre-existing cardiovascular disease, the direct and indirect cardiovascular effects of COVID-19, and potential cardiac toxicities and medication interactions associated with therapeutic agents under investigation. Last, we review the impact of COVID-19 on cardiovascular health care workers and health systems and offer considerations to optimize cardiovascular care for patients with and without this illness.
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Leadership Page {#sec3}
===============

 {#sec3.1}

### Finding Refuge in the ACC Family in Unprecedented Times {#sec3.1.1}
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### Long-Term Survival of Asymptomatic Patients With Very Severe Aortic Stenosis: Early Surgery Versus Conventional Treatment {#sec4.1.1}
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